Abstract
The introduction of tyrosine kinase inhibitor treatment for CML marks one of the major success stories in the recent history of medicine. However, eradication of disease is almost never attained, because, unlike the vast majority of more differentiated cells, leukemic stem cells withstand TKIs, necessitating life-long treatment. Besides, although a relatively infrequent event under treatment with TKIs, refractory leukemic stem cells may sometimes give rise to disease transformation. In this article, we will review the definitions of CML stem cells, explain how BCR-ABL induces perturbations of critical signal transduction pathways and summarize specific characteristics that cause refractoriness of CML stem cells against TKIs. Furthermore, events that are responsible or related to transformation of the disease into blast crisis will be discussed and new research directions that should lead to successful ways to attack leukemic stem cells are proposed.
Keywords: CML, stem cells, tyrosine kinase inhibitors, immunophenotyping, signal transduction
Current Stem Cell Research & Therapy
Title: Towards Cure of CML: Why We Need to Know More About CML Stem Cells?
Volume: 4 Issue: 3
Author(s): Jeroen J.W.M. Janssen, Gerrit J. Schuurhuis, Monique Terwijn and Gerrit J. Ossenkoppele
Affiliation:
Keywords: CML, stem cells, tyrosine kinase inhibitors, immunophenotyping, signal transduction
Abstract: The introduction of tyrosine kinase inhibitor treatment for CML marks one of the major success stories in the recent history of medicine. However, eradication of disease is almost never attained, because, unlike the vast majority of more differentiated cells, leukemic stem cells withstand TKIs, necessitating life-long treatment. Besides, although a relatively infrequent event under treatment with TKIs, refractory leukemic stem cells may sometimes give rise to disease transformation. In this article, we will review the definitions of CML stem cells, explain how BCR-ABL induces perturbations of critical signal transduction pathways and summarize specific characteristics that cause refractoriness of CML stem cells against TKIs. Furthermore, events that are responsible or related to transformation of the disease into blast crisis will be discussed and new research directions that should lead to successful ways to attack leukemic stem cells are proposed.
Export Options
About this article
Cite this article as:
Janssen J.W.M. Jeroen, Schuurhuis J. Gerrit, Terwijn Monique and Ossenkoppele J. Gerrit, Towards Cure of CML: Why We Need to Know More About CML Stem Cells?, Current Stem Cell Research & Therapy 2009; 4 (3) . https://dx.doi.org/10.2174/157488809789057428
DOI https://dx.doi.org/10.2174/157488809789057428 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry Signal Transduction and Photodynamic Therapy
Current Signal Transduction Therapy Distribution, Bioactivities and Therapeutical Potentials of Pentagalloylglucopyranose
Current Bioactive Compounds Anti-Gene Strategies to Down-Regulate Gene Expression in Mammalian Cells
Current Pharmaceutical Design Gene Modified Cell Transplantation for Vascular Regeneration
Current Gene Therapy Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Erythropoietic Porphyrias: Animal Models and Update in Gene-Based Therapies
Current Gene Therapy Translational Gap in Glioma Research
Anti-Cancer Agents in Medicinal Chemistry Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation
Current Stem Cell Research & Therapy Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
Current Pharmaceutical Design Neutral Actions of Raltegravir on Adipogenesis, Glucose Metabolism and Lipolysis in 3T3-L1 Adipocytes
Current HIV Research Dibenzofurans from Lichens – A Pharmacological Overview
Current Topics in Medicinal Chemistry Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story
Current Chemical Biology The Emerging Role of Bcr-Abl-Induced Cystoskeletal Remodeling in Systemic Persistence of Leukemic Stem Cells
Current Drug Delivery MicroRNAs in Cancer: Small Molecules, Big Chances
Anti-Cancer Agents in Medicinal Chemistry Phytochemical Profiles, Antioxidant and Antibacterial Activities of 11 Phellinus Mushrooms Collected in Thailand
The Natural Products Journal Intracellular ROS Generation Mediates Maleimide-induced Cytotoxicity in Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Exploitation of Apoptosis Pathways for Childhood Leukemia
Current Pediatric Reviews EphA2-Dependent Molecular Targeting Therapy for Malignant Tumors
Current Cancer Drug Targets Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry